MARKET

ORMP

ORMP

Oramed Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.770
+0.170
+3.70%
Opening 15:28 07/05 EDT
OPEN
4.510
PREV CLOSE
4.600
HIGH
4.811
LOW
4.460
VOLUME
167.62K
TURNOVER
457.42K
52 WEEK HIGH
31.54
52 WEEK LOW
3.590
MARKET CAP
183.95M
P/E (TTM)
-4.9461
1D
5D
1M
3M
1Y
5Y
Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.
PR Newswire · 06/01 11:55
Oramed granted U.S. combination therapy patent for oral insulin
Oramed Pharma (NASDAQ:ORMP) said on Tuesday that the United States Patent and Trademark Office had granted a patent for methods and compositions for treating diabetes. The patent is for methods and
Seekingalpha · 05/24 13:37
BRIEF-Oramed Granted U.S. Patent For Oral GLP-1 & Insulin For Diabetes Treatment
reuters.com · 05/24 12:11
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the...
PR Newswire · 05/24 12:10
Oramed Pharmaceuticals Secures US Patent for Oral Diabetes Treatment
MT Newswires · 05/24 10:16
Oramed to Present at H.C. Wainwright Global Investment Conference
Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person c...
PR Newswire · 05/18 11:55
--Aegis Capital Adjusts Price Target for Oramed Pharmaceuticals to $30 From $35, Maintains Buy Rating
MT Newswires · 05/16 10:20
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
More
No Data
Learn about the latest financial forecast of ORMP. Analyze the recent business situations of Oramed Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ORMP stock price target is 31.67 with a high estimate of 40.00 and a low estimate of 20.00.
High40.00
Average31.67
Low20.00
Current 4.770
EPS
Actual
Estimate
-0.18-0.13-0.09-0.04
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 113
Institutional Holdings: 9.52M
% Owned: 24.68%
Shares Outstanding: 38.56M
TypeInstitutionsShares
Increased
34
1.90M
New
12
558.39K
Decreased
28
1.29M
Sold Out
24
695.30K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.15%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Non-Executive Chairman/Independent Director
Kevin Rakin
Chief Executive Officer/President/Director
Nadav Kidron
Chief Financial Officer/Treasurer
David Silberman
Chief Operating Officer
Joshua Hexter
Chief Scientific Officer/Director
Miriam Kidron
General Counsel/Secretary
Netanel Derovan
Other
Michael Rabinowitz
Independent Director
Aviad Friedman
Independent Director
Arie Mayer
Independent Director
Yadin Rozov
Independent Director
Leonard Sank
No Data
No Data
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.

Webull offers kinds of Oramed Pharmaceuticals, Inc. stock information, including NASDAQ:ORMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORMP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ORMP stock methods without spending real money on the virtual paper trading platform.